Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are two of the more common non-Hodgkin lymphomas (NHLs); these aggressive and indolent disorders represent the two classic “faces” of lymphoma. Recently, several novel therapeutic classes, including targeted agents, next-generation antibodies, and CAR-T cell therapy, have emerged as active strategies in diverse DLBCL and FL settings. These developments have challenged the use of standard immunochemotherapy-focused management and led to a new era of care in which increasingly, baseline factors can help identify patients who may benefit from the use of innovative therapeutics.

 

This live web broadcast will provide learners with a clinical grounding on how new science is changing FL and DLBCL management. Each scientific seminar will open with a case-based “Tumor Board” session that will explore important factors in the selection and use of newer therapeutics, followed by a concise expert take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive NHL. Register today to learn how the experts are rising to the challenge of modern patient management for aggressive and indolent NHL. Don’t miss this informative event!